Terns Pharma ends obesity drug program after mid-stage trial data
21/10/2025 21:54
Oct 21 (Reuters) - Terns Pharmaceuticals TERN.O said on Tuesday it will stop developing its experimental obesity drug after a mid-stage trial showed modest weight loss and raised safety concerns. (Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona) ((Kamal.Choudhury@thomsonreuters.com))
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.